Please login to the form below

Not currently logged in
Email:
Password:

Regeneron

This page shows the latest Regeneron news and features for those working in and with pharma, biotech and healthcare.

Sanofi gets cardio outcomes claim for Praluent in EU

Sanofi gets cardio outcomes claim for Praluent in EU

and could lead to a fightback for Sanofi’s drug, which is partnered with Regeneron. ... Sanofi booked 250m from Praluent last year, up 54%, while Regeneron said it made $181m from the drug.

Latest news

More from news
Approximately 50 fully matching, plus 126 partially matching documents found.

Latest Intelligence

  • Immuno-oncology in 2019: the rapid evolution continues Immuno-oncology in 2019: the rapid evolution continues

    In addition to the PD-1 inhibitors Keytruda and Opdivo, there are four PD-L1 inhibitors: Roche’s Tecentriq, AstraZeneca’s Imfinzi, Pfizer and Merck’s Bavencio and Sanofi and

  • Regeneron and Bluebird sign $100m cell therapies deal Regeneron and Bluebird sign $100m cell therapies deal

    If Regeneron chooses not to opt-in, it will receive milestone payments and royalties from Bluebird on any potential resulting products. ... The deal involves Regeneron making a $100 million investment in Bluebird stock, at a premium of 59% over its

  • The good, the bad and the ugly The good, the bad and the ugly

    Ophthalmology. Ophthalmology is dominated by a small number of the same therapies marketed by different companies in different regions; Regeneron, Bayer and Santen all market Eylea, whereas Novartis and Roche market ... Regeneron remains the leading

  • Deal Watch October 2016 Deal Watch October 2016

    330. Ocular Therapeutics (US). Regeneron (US). Licence collaboration. Hydrogel sustained release aflibercept (Eylea) for wet macular degeneration.

  • Deal Watch September 2016 Deal Watch September 2016

    4, 325. Regeneron / Teva. Licence. Fasinumab in P3 for osteoarthritis pain, upfront payment $250m [excludes rights to Japan, Korea and other Asian markets].

More from intelligence
Approximately 1 fully matching, plus 14 partially matching documents found.

Latest appointments

  • Tiziana Life Sciences appoints clinical sciences VP Tiziana Life Sciences appoints clinical sciences VP

    Prior to this, Dr Evans held a number of scientific leadership positions while at Amgen, Johnson &Johnson and Regeneron.

  • Regeneron taps Pfizer for CFO Regeneron taps Pfizer for CFO

    Robert Landry succeeds Murray Goldberg. Former Pfizer senior VP Robert Landry has joined Regeneron as senior VP, finance, and will later take over as chief financial officer. ... We are extremely fortunate that Murray will stay at Regeneron through 2014

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Communications

Formerly known as Packer Forbes Communications, Four Health Communications is an award-winning, integrated healthcare communications agency for pharma, biotech, NGOs...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics